Buyer/Partner (location)

Licensor/Partner (location)

Value (M)

Type/product area

Terms/details

Date

DECEMBER

Adaptimmune Therapeutics plc (Oxford, U.K.)

Bellicum Pharmaceuticals Inc. (Houston)

N/A

Staged collaboration to evaluate, develop and commercialize next-generation T-cell therapies

The companies will evaluate Bellicum's GoTCR technology (inducible MyD88/CD40 co-stimulation, or iMC) with Adaptimmune's affinity-optimized SPEAR T-cells for the potential to create enhanced TCR product candidates

12/20/16

Almirall SA (Barcelona, Spain)

Mercachem BV

$6.04

Exclusive discovery collaboration focusing on the development of oral cytokine blockers for the treatment of inflammatory skin diseases

Mercachem will perform iterative optimization campaigns toward the identification of candidates for further development at Almirall, and Almirall will fund Mercachem's research in that area and perform any future preclinical, clinical, regulatory and commercial activities; Mercachem will get €1M (US$1.04M) up front, along with research fees, and is eligible to receive development milestones of up to €5.5M

12/22/16

Ascendance Biotechnology Inc. (Medford, Mass.)

GE Healthcare

N/A

Provides Ascendance a right to manufacture, market and sell the GE Healthcare Cytiva brand of human stem cell-derived cardiomyocytes used for evaluating potential cardiotoxicity

Terms were not disclosed

12/29/16

Benitec Biopharma Ltd. (Sydney)

Nantworks Inc. (Culver City, Calif.)

N/A

Exclusive, worldwide sublicensing agreement to enable Benitec, in collaboration with Nantworks, to develop a clinical-stage asset to treat head and neck squamous cell carcinoma using a gene silencing approach that targets EGFR

The asset is composed of a DNA plasmid which produces an antisense RNA to silence EGFR

12/27/16

Bioavenir Ltd. (Tel Aviv, Israel)

Xbrane Biopharma AB (Stockholm)

$0.11

Distribution agreement for sales and marketing of Spherotide, a depot formulation of triptorelin used primarily in the treatment of prostate cancer, endometriosis and uterine fibroids, for the Israeli market

The companies will share profits from sales in Israel and Xbrane will receive a license fee of SEK1M (US$108,337), divided in up-front and milestone payments, until the product is launched

12/22/16

Bluebird Bio Inc. (Cambridge, Mass.)

Apceth Biopharma GmbH (Munich, Germany)

N/A

Strategic manufacturing agreement for the future European commercial production of Bluebird's Lenti-D candidate for cerebral adrenoleukodystrophy and its Lentiglobin candidate for transfusion-dependent beta-thalassemia

Apceth will perform clinical manufacturing, process validation activities and commercial manufacturing for both

12/16/16

Bristol-Myers Squibb Co. (New York)

Psioxus Therapeutics Ltd. (London)

$936

Agreement for NG-348, an armed oncolytic virus that delivers the genes for two T-cell mobilizing proteins; the product is in preclinical development and is intended for use against a range of solid tumors

Psioxus will receive $50M up front and also will be paid to complete preclinical development of NG-348; in addition to $886M in development, regulatory and sales-based milestones, BMS will pay royalties on net sales

12/21/16

Bristol-Myers Squibb Co. (New York)

Calithera Biosciences Inc. (South San Francisco)

N/A

Collaboration to evaluate the checkpoint inhibitor, Opdivo (nivolumab, BMS), in combination with Calithera's CB-839 in patients with clear cell renal cell carcinoma

CB-839 is an orally administered glutaminase inhibitor in phase I/II studies

12/22/16

Cambridge Innovation Capital plc (Cambridge, U.K.)

IP Group plc (London)

N/A

Agreement to create a new spinout company from the Wellcome Trust Sanger Institute, called Microbiotica Ltd.

With a founding investment of £8M (US$9.9M), the company plans to move multiple live bacteriotherapy programs into development

12/20/16

Catalyst Biosciences Inc. (South San Francisco)

Wyeth LLC (subsidiary of Pfizer Inc.; New York)

N/A

Agreement for all rights to the manufacturing process for marzeptacog alfa

Marzeptacog alfa (activated) is a next-generation factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors

12/20/16

Celgene Corp. (Summit, N.J.)

Evotec AG (Hamburg, Germany)

$295

Five-year drug discovery pact in neurodegenerative disease

Evotec is banking $45M up-front and stands to earn up to $250M more in per-program milestones; the five-year alliance will deploy Evotec's induced pluripotent stem cell (iPSC) platform in the hunt for novel molecules that could have an impact on conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease; Evotec is entitled to low double-digit royalties on eventual product sales

12/19/16

Celgene Corp. (Summit, N.J.)

Northern Biologics Inc. (Toronto)

N/A

Option agreement for Celgene to take forward Mosaic's key asset, MSC-1, a first-in-class antibody that targets leukemia inhibitory factor

Deal terms were not disclosed

12/20/16

Celgene Corp. (Summit, N.J.)

Triphase Accelerator Corp. (Toronto)

N/A

Collaboration in which Celgene has an option to acquire all Triphase assets relating to TRPH-222, an antibody-drug conjugate in development for lymphoma

Triphase received an undisclosed up-front payment and will control and retain all commercial rights to the program; if Celgene exercises its option to acquire, it will take over development and commercialization in exchange for development, regulatory and sales milestone payments to Triphase

12/22/16

Chong Kun Dang Pharmaceuticals

Can-Fite Biopharma Ltd. (Petach Tikva, Israel)

$3.50

Agreement for Can-Fite to be the exclusive distributor of CF102 (namodenoson) to treat liver cancer in South Korea

The $500,000 up-front payment arrives as Can-Fite continues to advance through completion of its current phase II trial as a second line treatment for hepatocellular carcinoma and into phase III; Can-Fite stands to earn up to $3M in up-front and milestone payments, plus royalties on net sales of 23%

12/22/16

Chugai Pharmaceutical Co. Ltd. (Tokyo)

Pharmamar SA (Madrid, Spain)

$131.40

Exclusive license for its third marine-derived cancer drug, PM1183 (lurbinectedin), in Japan

Pharmamar will get an up-front payment of €30M (US$31.4M), along with double-digit tiered royalties, and will also be eligible for receiving payments in line with the progress of development and sales milestones, potentially worth more than €100M

12/23/16

Circuit Therapeutics Inc. (Menlo Park, Calif.)

Lundbeck A/S (Copenhagen)

N/A

Research collaboration to extend the knowledge around neural circuits associated with psychiatric symptoms and the development of novel medicines to treat those symptoms

Further details were not disclosed

12/20/16

Corporate Venture Capital Ltd. (subsidiary of Sosei Group Corp.; Tokyo)

Pluristem Therapeutics Inc. (Haifa, Israel)

$11

Binding term sheet to establish a Japanese corporation to develop and commercialize Pluristem's PLX-PAD cell therapy product in Japan

Pluristem will own 35% of the newco in return for its contribution of a perpetual license to commercialize PLX-PAD for critical limb ischemia (CLI) in Japan; proprietary rights related to PLX-PAD will be exclusively owned by Pluristem. Sosei CVC's investment fund, Sosei RMF1, together with additional Japanese investors, will raise and invest approximately $11M, equivalent to about ¥1.3B in return for ownership of 65% of the newco, which will investigate CLI as the first indication

12/21/16

Crispr Therapeutics AG (Basel, Switzerland) and Intellia Therapeutics Inc. (Cambridge, Mass.); ERS Genomics (Dublin) and Caribou Biosciences Inc. (Berkeley, Calif.)

Charpentier, the University of Vienna and the University of California

N/A

Global intellectual property agreement for CRISPR/Cas9 under which each signatory will recognize the other's IP rights and IP licensing deals, and will cooperate on maintaining the patent estate and will coordinate efforts on prosecuting, defending and enforcing their shared IP rights

The move will give each company – and their licensees – full freedom to operate on a global basis with respect to the CRISPR/Cas9 patents held by Emmanuelle Charpentier, the University of Vienna and the University of California; the agreement complements the existing cooperation between Charpentier (Crispr) and Jennifer Doudna (Intellia) and their respective institutions in the patent interference proceedings they have brought against the Broad Institute, Massachusetts Institute of Technology and Harvard University

12/19/16

Dermavant Sciences (subsidiary of Roivant Sciences Inc.)

Portola Pharmaceuticals Inc.

N/A

Exclusive worldwide licensing agreement for the development and commercialization of the dual spleen tyrosine kinase and janus kinase inhibitor cerdulatinib in topical applications beyond oncology

Cerdulatinib is currently being investigated in an ongoing phase IIa trial in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies; Portola retains full rights to all non-topical formulations of cerdulatinib, including oral formulations

12/22/16

Elsalys Biotech (Lyon, France)

Transgene SA (Lyon, France)

N/A

Elsalys acquired development and marketing rights for TG3003 anti-CD115, a monoclonal antibody that inhibits a highly immunosuppressive macrophage subpopulation: type-2 macrophages

Transgene will be eligible to receive milestone payments until the medicinal product is registered and will receive royalties based on future sales

12/19/16

Gradalis Inc. (Dallas)

Genentech Inc. (South San Francisco; unit of Roche Group)

N/A

Collaboration to test its Vigil EATC (engineered autologous tumor cell) therapy in combination with Genentech's anti-PD-1 drug Tecentriq (atezolizumab) in a phase II study in women with advanced ovarian cancer

The study, sponsored by Gradalis, will evaluate the safety and antitumor activity of the combination, using biomarkers to measure the antitumor systemic immune response generated by Vigil alone, atezolizumab alone or the combination of the two drugs

12/22/16

Healthcare Royalty Partners and Dyax Corp. (Burlington, Mass.)

Xoma Corp. (Berkeley, Calif.)

N/A

Company will streamline operations so it can focus on XOMA 358 clinical development, monetize noncore assets and strengthen its balance sheet

The company sold its rights to Healthcare Royalty Partners under license agreements relating to Trumenba, a meningococcal group B vaccine marketed by Pfizer Inc., of New York, on which Xoma has been receiving low single-digit royalties from commercial sales; the second agreement is with Dyax Corp., of Burlington, Mass.; Xoma also said it is reducing its headcount by 57 positions.

12/23/16

Hemostemix Inc. (Toronto)

Drive Capital

N/A

Management contractor agreement in which Drive will oversee and manage all aspects of a corporate reorganization, including the appointment of a new board and management team

The agreement has a term of two years

12/27/16

Imab (Shanghai)

Ferring Pharmaceuticals SA (Saint Prex, Switzerland)

N/A

Exclusive Asian rights for olamkicept in autoimmune diseases

Imab will maintain the rights to further develop, manufacture and market olamkicept in Asia and has an option to obtain worldwide rights in the future

12/30/16

I-MAB (Shanghai, China)

Ferring Pharmaceuticals SA (Saint-Prex, Switzerland)

N/A

Licensing agreement, giving I-MAB exclusive rights to olamkicept (pINN), a recombinant protein inhibitor of the interleukin-6 pathway, in Asia

I-MAB is responsible for funding further product development in autoimmune disease and will receive an exclusive license in Asia with the option for worldwide use

12/20/16

Incyte Corp. (Wilmington, Del.)

Merus NV (Utrecht, the Netherlands)

$3,000

Agreement for Merus' Bioclonics platform focused on oncology

Merus gets $120M up front, an equity investment of $80M more, and about another $2.8B if milestones are reached; they agreed to work on as many as 11 bispecific antibody programs; for one preclinical effort, Merus will retain all rights in the U.S. and Incyte will develop and commercialize approved products arising from the program outside the country; if any products are approved, each company has agreed to pay the other tiered royalties ranging from 6% to 10%; Merus also has the option to co-fund development of product candidates that might emerge from two other programs; for any program where Merus does so, the firm would be responsible for 35% of global development costs in exchange for a 50% share of U.S. profits and losses, as well as tiered royalties ranging from 6% to 10% on ex-U.S. sales by Incyte; Merus also has the right to elect to provide up to 50% of detailing activities for product candidates arising from one of these programs in the U.S., too

12/22/16

Innavirvax (Evry, France)

FIT Biotech OY (Tempere, Finland)

N/A

Agreement to combine immunotherapies, VAC-3S and FIT-06, with the goal of developing a functional cure for HIV

The partners plan to start a phase II trial in 2017 to evaluate the safety, tolerability, immunogenicity, and efficacy of FIT's DNA-based HIV vaccine in combination with Innavirvax's immunoprotective vaccine; though Innavirvax will conduct the study, the results will be co-owned by the two companies

12/22/16

Innovus Pharmaceuticals Inc. (San Diego)

NTC Srl (Milan, Italy)

N/A

In-licensing agreement for Lertal food supplement tablets for the management of allergic rhinitis from NTC

The bilayer tablets contain a fast-release layer of the antihistamine perilla and a sustained-release layer of quercetin and vitamin D3; Innovus agreed to pay an undisclosed up-front, transfer price and sales milestones during the term of the agreement

12/20/16

Ipsen SA (Paris)

Exelixis Inc. (South San Francisco)

$10

Amended exclusive collaboration and licensing agreement for the commercialization and continued development of cabozantinib, to include commercialization rights in Canada for Ipsen where Ipsen has an established business

Exelixis will receive a $10M up-front payment, and is eligible to receive regulatory milestones, for the approvals of cabozantinib in Canada for advanced renal cell carcinoma (RCC) after prior treatment, for first-line RCC, and advanced hepatocellular carcinoma (HCC), as well as additional regulatory milestones for potential further indications

12/22/16

Knight Therapeutics Inc. (Montreal)

Astrazeneca plc (London)

N/A

Exclusive deal for the rights to Movantik (naloxegol) in Canada and Israel

Movantik is a once-daily, oral, peripherally acting mu-opioid receptor antagonist approved in Canada for the treatment of opioid-induced constipation in adults with noncancer pain who have had an inadequate response to laxatives

12/16/16

Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo)

SBI Holdings Inc. (Japan)

N/A

Nonbinding letter of intent to establish a joint venture designed to organize and manage special purpose entities to finance the development of ophthalmic drugs and devices

The LOI contemplates that the joint venture will be funded 51% by Kubota Pharma and 49% by SBI; Kubota Pharma and SBI have entered negotiations for a definitive joint venture agreement

12/27/16

Les Laboratoires Servier SAS (Neuilly-sur-Seine, France)

Ose Immuno-therapeutics SA (Nantes, France)

$284.20

Worldwide license option agreement for the development and commercialization of Ose's Effi-7

Ose is granting Servier an option for exclusive rights in exchange for up to €272M (US$284.2M), including an up-front payment of €10.25M and additional payments of €30M upon the exercise of a two-step option license enabling the development of Effi-7 up to the completion of a phase II trial planned in ulcerative colitis (UC); further payments will be linked to the achievement of clinical development and registration in multiple indications, as well as sales milestones with double-digit royalties

12/29/16

Mallinckrodt Pharmaceuticals plc (Chesterfield, U.K.)

Mesoblast Ltd. (New York)

N/A

Mesoblast will exclusively negotiate a commercial and development partnership for two of Mesoblast's Tier 1 product candidates, MPC-06-ID in moderate/severe chronic low back pain and MSC-100-IV in acute graft versus host disease

Mallinckrodt has an exclusive period of up to nine months to conclude commercial and development agreements for the two candidates in all territories outside of Japan and China; Mallinckrodt will purchase approximately 20.04M (4.99%) of Mesoblast's ordinary shares at a price of A$1.4761 per share

12/30/16

Medivir AB (Stockholm)

Tetralogic Pharmaceuticals Corp. (Paoli, Pa.) and its wholly owned subsidiary

$165.00

Completed the sale of the SMAC mimetic program, including clinical-stage asset birinapant and topical HDAC inhibitor remetinostat

Terms of the deal include a purchase price of $12M payable in cash at closing and milestone payments of up to $153M, plus additional earn-out payments based on annual net sales of birinapant

12/30/16

Merck & Co. Inc. (Kenilworth, N.J.)

Noxxon Pharma NV (Berlin)

N/A

Collaboration agreement to conduct a phase II/III trial testing Noxxon's anti-CXCL12 agent, NOX-A12, in combination with Merck's anti-PD-1 antibody Keytruda (pembrolizumab) in patients with metastatic solid tumors that do not usually respond to checkpoint inhibitor monotherapy

The goal of the two-part, open-label study is to evaluate pharmacodynamic effects and safety of NOX-A12 as a monotherapy, in addition to safety and efficacy of NOX-A12 in combination with Keytruda in patients with metastatic colorectal and pancreatic cancer; a total of 20 patients will be recruited, 10 of each cancer type; Noxxon will be the sponsor of the study, which will be conducted in Europe

12/16/16

Novartis AG (Basel, Switzerland)

Protagen AG (Dortmund, Germany)

N/A

Collaboration agreement using Protagen's Serotag technology to discover prediction and patient stratification markers for an undisclosed drug in development by Novartis

Terms were not disclosed

12/21/16

Novartis AG (Basel, Switzerland)

Conatus Pharmaceuticals Inc. (San Diego)

$707

The global option, collaboration and license deal for development of emricasan, an oral pan-caspase inhibitor

The pact provides Conatus $50M up front, $7M after the license option is exercised, and the capability of borrowing up to $15M in the form of convertible promissory notes under an investment agreement with the pharma giant; also included: as much as $650M in milestone payments plus tiered double-digit royalties on emricasan single-agent sales, as well as tiered single- to double-digit royalties on sales of combination products that contain the drug

12/21/16

Novartis AG (Basel, Switzerland)

Sunovion Pharmaceuticals Inc. (Marlborough, Mass.)

N/A

Exclusive license agreement for the U.S. commercialization rights to three approved medicines – Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder, Seebri Neohaler (glycopyrrolate) inhalation powder and Arcapta Neohaler (indacaterol) inhalation powder – indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease

Novartis will continue to manufacture those products

12/22/16

Novartis AG (Basel, Switzerland)

Ligand Pharmaceuticals Inc. (San Diego)

N/A

Global license and supply agreements for the development and commercialization of a Captisol-enabled oral liquid formulation of trametinib, a kinase inhibitor currently indicated as a single agent or in combination with dabrafenib to treat patients with unresectable or metastatic melanoma with BRAFV600 mutations

Ligand will be eligible to receive a license fee, royalties on future net sales and revenue from Captisol material sales; Novartis will be responsible for all costs related to the program

12/23/16

Ono Pharmaceutical Co. Ltd. (Osaka, Japan)

Ligand Pharmaceuticals Inc. (San Diego)

N/A

Worldwide license deal under which Ono will use the Omnirat, Omnimouse and Omniflic platforms to discover fully human mono- and bispecific antibodies

Ligand is eligible for annual platform access payments, development milestones and royalties; Ono will be responsible for all costs

12/23/16

Orexigen Therapeutics Ireland Ltd. (unit of Orexigen Therapeutics Inc.; San Diego)

Biologix FZCO

N/A

Commercialization and distributorship agreement in the Middle East for Contrave (naltrexone HCl/buproprion HCl prolonged release) monotherapy for weight management in overweight or obese adult patients

This deal covers 10 countries in the Middle East: Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, Bahrain, Lebanon, Jordan, Iraq and Iran; Biologix will be responsible for obtaining regulatory approvals and local product registrations in each of the 10 countries and for all commercialization activities; Orexigen will supply Contrave to Biologix at an agreed transfer price

12/20/16

Otsuka Pharmaceutical Co. Ltd. (Cambridge, Mass.)

Akebia Therapeutics Inc.

$1,030

U.S. development and commercialization collaboration for vadadustat, an oral hypoxia-inducible factor stabilizer to treat anemia associated with chronic kidney disease

Akebia is set to receive $265M in committed funds, including a payment of $125M at signing – which occurred during a ceremony in Tokyo on Sunday – and approximately $35M more in the first quarter of 2017, based on historic development costs; Otsuka also agreed to provide $105M, prepaid in quarterly payments, for ongoing costs of the vadadustat global development program for vadadustat – more, if the development program exceeds the projected budget – along with potential development and commercial milestones of up to $765M, raising the potential value of the transaction to more than $1B; companies will contribute equally to commercialization efforts and share equally costs and revenue in the U.S.

12/21/16

Pfizer Inc. (New York)

Bioinvent International AB (Lund, Sweden)

$500

Immuno-oncology deal for five antibodies moved toward commercialization, validating targets and antibodies that act on them through functional screening of large antibody libraries against clinical material from patients and healthy volunteers

The $500M deal includes $10M initially, including an equity investment of $6M plus $4M as an upfront payment and early research funding.

12/22/16

Promab Biotechnologies Inc. (Richmond, Calif.)

Helix Biopharma Corp. (Toronto)

N/A

Nonbinding letter of intent to develop cell-based therapies

The letter calls for both companies to complete a due diligence and establish a collaboration to develop CAR T therapies for hematological malignancies and solid tumors; the collaboration will seek to exploit Helix's single-domain antibodies-based CAR T and Promab's vector designs, antibodies library and cell-based production know-how

12/23/16

Purdue Pharma LP (Stamford, Conn.)

Shionogi Inc. (subsidiary of Shionogi & Co. Ltd.; Osaka, Japan)

N/A

Alliance for the joint U.S. launch and commercialization of Symproic (naldemedine)

The peripherally acting mu opioid receptor antagonist, designed to treat opioid-induced constipation in adults with chronic non-cancer pain, is under review by the FDA with a PDUFA date of March 23, 2017

12/20/16

Quintiles IMS Holdings Inc.

Bristol-Myers Squibb Co. (New York), Eli Lilly and Co. (Indianapolis), Merck KGaA (Darmstadt, Germany) and Pfizer Inc. (New York)

N/A

Collaborative initiative to ferret out real-world data on the use of cancer treatments across seven top European markets

The Collaboration for Oncology Data in Europe, or CODE, is funded both by QuintilesIMS and its four initial partners

12/29/17

Roche Holding AG (Basel, Switzerland)

Immunext Inc. (Lebanon, N.H.)

$400

Deal focused on developing therapies to modulate the immune system for the treatment of inflammation and autoimmune diseases

Immunext will grant Roche an exclusive global license to develop and commercialize therapeutics that agonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway; Immunext stands to earn payments for achieving certain preclinical, development and commercial milestones under the agreement, as well as tiered royalties up to double digits on sales of any resulting products

12/21/16

Spring Bank Pharmaceuticals Inc. (Hopkinton, Mass.)

Arbutus Biopharma Corp. (Vancouver, British Columbia)

N/A

Collaboration on preclinical studies in chronic hepatitis B virus involving co-administration of Spring Bank's SB 9200, an oral selective immune-modulator, and Arbutus Biopharma's AB-423, a capsid assembly inhibitor

Financial terms were not disclosed

12/20/16

Strongbridge Biopharma plc (Trevose, Pa.)

Taro Pharmaceutical Industries Ltd. (Hawthorne, N.Y.)

$8.50

Agreement in which Taro sold U.S. rights to Keveyis (dichlorphenamide) to Strongbridge in exchange for up-front and deferred payments of $8.5M in two installments

Taro also is entitled to receive additional future payments upon the achievement of certain sales milestones; Keveyis was approved by the FDA in August 2015 to treat primary hyperkalemic and hypokalemic period paralysis and has orphan designation through August 2022; Strongbridge expects to launch the product commercially in April 2017

12/27/16

SWK Holdings Corp.

Opiant Pharmaceuticals Inc. (Santa Monica, Calif.)

$17.50

Agreement for SWK to acquire rights to certain royalties and milestone payments related to the sales of Narcan nasal spray to treat opioid overdose for up to $17.5M

The company received $13.7M at closing and is eligible to receive an additional $3.75M contingent on the achievement of certain net sales milestones; Torreya Partners LLC acted as financial adviser and DLA Piper LLC acted as legal adviser to Opiant on the transaction

12/19/16

Taiho Pharmaceutical Co. Ltd. (Tokyo)

X-Chem Inc. (Waltham, Mass.)

$352

Multitarget drug discovery collaboration granting the latter access to X-Chem's DEX technology, which is based on DNA-encoded libraries of small molecules with more than 120B molecules

The aim of the collaboration is to discover lead structures for complex drug targets in multiple therapeutic areas with unmet medical need; under the terms of this new agreement, X-Chem will receive an up-front payment as well as potential preclinical, clinical and regulatory milestone payments and sales milestone payments up to a total of $352M; Taiho has an exclusive option to license any programs generated in the course of the collaboration; X-Chem will also receive royalties for each successfully commercialized drug that results from a licensed collaboration program

12/21/16

Tissuegene Inc. (Rockville, Md.)

Biolife Solutions Inc. (Bothell, Wash.)

N/A

10-year supply agreement with Tissuegene, which has incorporated Biolife's Cryostor cryopreservation media into its manufacturing process for the osteoarthritis drug candidate Invossa (tonogenchoncel-L)

Following trials of the candidate in South Korea in July, Tissuegene completed U.S. phase II trials of Invossa and received an FDA special protocol assessment for phase III trials scheduled to begin in the second quarter of 2017

12/21/16

Trieza Therapeutics Inc. (Cambridge, Mass.)

Abzena plc (Cambridge, U.K.)

$35

License agreement in which Abzena granted Trieza an exclusive, worldwide, royalty-bearing, sublicensable license to an undisclosed antibody sequence created using the group's Composite Human Antibody technology, for exploitation in conjunction with Trieza's viral vector technology to develop therapies in oncology

Abzena could receive up to $35M in development and commercial milestones, plus royalties on the sale of licensed products containing the Abzena sequence

12/23/16


Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.

For more information about individual companies and/or products, see Thomson Reuters Cortellis.